Optinose announced that XHANCE (fluticasone propionate) has been added to Express Scripts' national formularies, including the National Preferred, Flex, and Basic formularies, among the large commercial formularies in the U.S. with more than 24 million lives. Chronic sinusitis (also referred as chronic rhinosinusitis) affects approximately 30 million adults in the United States. Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.

The ReOpen clinical trial program was the first ever controlled trial program was the first evercontrolled trial program the first ever controlled trial program the company is aware of to demonstrate significant improvement in both symptoms and inflammation inside the sinuses for patients with chronic sinusitis, regardless of whether nasal polyps are present, and to demonstrate significant reduction in the number of acute exacerbations.